Literature DB >> 19322211

Chromatin maps, histone modifications and leukemia.

T Neff1, S A Armstrong.   

Abstract

Recent years have seen great advances in the understanding of epigenetic gene regulation. Many of the molecular players involved have recently been identified and are rapidly being characterized in detail. Genome scale studies, using chromatin immunoprecipitation followed by expression arrays ('ChIP-Chip') or next generation sequencing ('ChIP-Seq'), have been applied to the study of transcription factor binding, DNA methylation, alternative histone use, and covalent histone modifications such as acetylation, ubiquitination and methylation. Initial studies focused on yeast, and embryonic stem cells. Genome-wide studies are now also being employed to characterize cancer and specifically leukemia genomes, with the prospect of improved diagnostic accuracy and discovery of novel therapeutic strategies. Here, we review some of the epigenetic modifications and their relevance for leukemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322211     DOI: 10.1038/leu.2009.40

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  15 in total

1.  Whole-genome cancer analysis as an approach to deeper understanding of tumour biology.

Authors:  R L Strausberg; A J G Simpson
Journal:  Br J Cancer       Date:  2009-12-22       Impact factor: 7.640

2.  Sequencing histone-modifying enzymes identifies UTX mutations in acute lymphoblastic leukemia.

Authors:  B G Mar; L Bullinger; E Basu; K Schlis; L B Silverman; K Döhner; S A Armstrong
Journal:  Leukemia       Date:  2012-03-01       Impact factor: 11.528

3.  H3K27 Methylation Dynamics during CD4 T Cell Activation: Regulation of JAK/STAT and IL12RB2 Expression by JMJD3.

Authors:  Sarah A LaMere; Ryan C Thompson; Xiangzhi Meng; H Kiyomi Komori; Adam Mark; Daniel R Salomon
Journal:  J Immunol       Date:  2017-09-25       Impact factor: 5.422

4.  Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL.

Authors:  Matthew C Stubbs; Wonil Kim; Megan Bariteau; Tina Davis; Sridhar Vempati; Janna Minehart; Matthew Witkin; Jun Qi; Andrei V Krivtsov; James E Bradner; Andrew L Kung; Scott A Armstrong
Journal:  Clin Cancer Res       Date:  2015-02-16       Impact factor: 12.531

5.  Epigenetic landscape of acute myelogenous leukemia--moving toward personalized medicine.

Authors:  Gurpreet Lamba; Sayyed Kaleem Zaidi; Kimberly Luebbers; Claire Verschraegen; Gary S Stein; Alan Rosmarin
Journal:  J Cell Biochem       Date:  2014-10       Impact factor: 4.429

Review 6.  DNA methylation of cancer genome.

Authors:  Hoi-Hung Cheung; Tin-Lap Lee; Owen M Rennert; Wai-Yee Chan
Journal:  Birth Defects Res C Embryo Today       Date:  2009-12

Review 7.  Molecular genetics of AML.

Authors:  Daniel C Link
Journal:  Best Pract Res Clin Haematol       Date:  2012-10-23       Impact factor: 3.020

8.  NF-Y recruits Ash2L to impart H3K4 trimethylation on CCAAT promoters.

Authors:  Andrea Fossati; Diletta Dolfini; Giacomo Donati; Roberto Mantovani
Journal:  PLoS One       Date:  2011-03-21       Impact factor: 3.240

Review 9.  Sequencing technologies and genome sequencing.

Authors:  Chandra Shekhar Pareek; Rafal Smoczynski; Andrzej Tretyn
Journal:  J Appl Genet       Date:  2011-06-23       Impact factor: 3.240

10.  Leukemia gene atlas--a public platform for integrative exploration of genome-wide molecular data.

Authors:  Katja Hebestreit; Sören Gröttrup; Daniel Emden; Jannis Veerkamp; Christian Ruckert; Hans-Ulrich Klein; Carsten Müller-Tidow; Martin Dugas
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.